Anixa rises after lining up update on ovarian cancer therapy trial

Anixa Biosciences

30/03/2026 14:49

** Shares of biotech firm Anixa Biosciences ANIX.O rise 1.2% to $2.58

** Co says it will present data from an early-stage study of its experimental cell therapy for ovarian cancer at the Society of Gynecologic Oncology meeting in April

** The therapy, called lira-cel, trains immune cells to target a protein found largely in ovarian cancer cells, limiting damage to healthy tissue

** Drug is being tested in women with ovarian cancer, who have had a relapse after at least two prior treatments

** Co to run programme with Moffitt Cancer Centre

** Including session's move, stock down ~17% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))